» Articles » PMID: 35501263

Immune Checkpoint Inhibitor-related Thyroid Dysfunction

Overview
Publisher Elsevier
Specialty Endocrinology
Date 2022 May 2
PMID 35501263
Authors
Affiliations
Soon will be listed here.
Abstract

Immune-related adverse events (irAEs) are caused by immune checkpoint inhibitors in several organs including the endocrine glands. Thyroid dysfunction (thyroid irAEs) is often observed among endocrine irAEs and is induced by blockade of programmed cell death 1 (PD-1), programmed death ligand 1, or PD-1 plus cytotoxic T-lymphocyte antigen 4. Endocrinologically, destructive thyroiditis or hypothyroidism is observed in most cases, whereas hyperthyroidism (Graves' disease) is rare. Most patients who develop destructive thyroiditis or hypothyroidism subsequently require thyroid hormone replacement therapy. Thyroid irAE development is associated with prolonged survival in patients with non-small cell lung carcinoma. The incidence of thyroid irAEs is higher in patients who are positive versus negative for anti-thyroid antibodies at baseline, suggesting that these antibodies can predict thyroid irAE development. Cytotoxic T cells, especially CD4 T cells, are reportedly involved in the development of destructive thyroiditis. In this review, we describe the clinical features, potential biomarkers, and mechanism of thyroid irAEs.

Citing Articles

Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade.

Li Z, Liu S, Liu D, Yang K, Xiong J, Fang Z J Exp Clin Cancer Res. 2025; 44(1):84.

PMID: 40038799 PMC: 11881293. DOI: 10.1186/s13046-025-03318-6.


Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma.

Shang K, He Q, Xu X, Luo X, Zhao C, Liu L Ther Clin Risk Manag. 2025; 21():15-25.

PMID: 39802955 PMC: 11721357. DOI: 10.2147/TCRM.S489899.


Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors.

Iwama S, Kobayashi T, Arima H Nat Rev Endocrinol. 2025; .

PMID: 39779950 DOI: 10.1038/s41574-024-01077-6.


Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study.

Guo G, Jing Z, Dou W, Wang G, Dang J, Li Y Front Immunol. 2025; 15:1495460.

PMID: 39763663 PMC: 11700968. DOI: 10.3389/fimmu.2024.1495460.


Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients.

Iwamoto Y, Kimura T, Dan K, Iwamoto H, Sanada J, Fushimi Y Sci Rep. 2025; 15(1):390.

PMID: 39747534 PMC: 11695621. DOI: 10.1038/s41598-024-84488-9.